Ahmad H Awada
Overview
Explore the profile of Ahmad H Awada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials
Fey M, OReilly S, Awada A, Crowley J, Gelmon K
Curr Opin Oncol
. 2024 Aug;
36(5):418-420.
PMID: 39106404
No abstract available.
2.
Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Ponde N, et al.
Eur J Cancer
. 2021 Mar;
148:76-91.
PMID: 33740500
Background: Immune checkpoint inhibitors (ICIs) may cause potentially life-threatening adverse events (AEs), but the risk of cardiotoxicity has not been fully investigated. It is also unknown whether ICI combinations increase...
3.
Kourie H, Awada G, Awada A
Curr Opin Oncol
. 2016 May;
28(4):295-305.
PMID: 27153354
Purpose Of Review: The aim of this review is to draw the attention of the physicians and oncologists on the rare side-effects of checkpoint inhibitors not usually reported in clinical...
4.
Awada G, Kourie H, Awada A
Discov Med
. 2015 Sep;
20(108):33-41.
PMID: 26321085
Major advances in cancer research in the last two decades have provided us with a better understanding of the dynamics of the cancer cell and its microenvironment. This has consequently...
5.
Farhat F, Tfayli A, Fakhruddin N, Mahfouz R, Otrock Z, Alameddine R, et al.
Crit Rev Oncol Hematol
. 2012 Apr;
84(2):149-60.
PMID: 22494932
Despite major advances in cancer therapeutics, the prognosis for lung cancer patients is still poor and the median survival for patients presenting with advanced non-small cell lung cancer (NSCLC) is...
6.
Otrock Z, Hatoum H, Musallam K, Awada A, Shamseddine A
Crit Rev Oncol Hematol
. 2010 Aug;
79(2):103-11.
PMID: 20724177
Tumor growth and metastasis are dependent on angiogenesis. Inhibiting angiogenesis has therapeutic potentials for treating cancer. Researchers have identified many of the pathways involved in angiogenesis and proposed selective targeted...
7.
Otrock Z, Hatoum H, Awada A, Ishak R, Shamseddine A
Crit Rev Oncol Hematol
. 2009 Feb;
70(2):93-102.
PMID: 19186072
Tumor hypoxia is a common feature of many cancers. A master regulator of hypoxic response is the transcription factor hypoxia-inducible factor-1 (HIF-1). It functions as a master regulator of oxygen...